I'm LongbridgeAI, I can summarize articles.Medtronic (MDT) added 3.22% this week to close at $94.17, beating the S&P 500 by about 3.13 percentage points. The week started soft: Monday (31 Aug) opened low and settled at $90.65, then Tuesday (1 Sep) briefly touched $95.41, the week’s high. The following three sessions pulled back before Friday (4 Sep) ended above $94. Weekly amplitude was 5.92%, and average daily volume of 11.4m shares ran nearly half above the median, a notable pickup in turnover.
The Week
Medtronic (MDT) added 3.22% this week to close at $94.17, beating the S&P 500 by about 3.13 percentage points. The week started soft: Monday (31 Aug) opened low and settled at $90.65, then Tuesday (1 Sep) briefly touched $95.41, the week’s high. The following three sessions pulled back before Friday (4 Sep) ended above $94. Weekly amplitude was 5.92%, and average daily volume of 11.4m shares ran nearly half above the median, a notable pickup in turnover.
Key Events
The week’s main thread combined an earnings raise with two strategic moves. On Tuesday (1 Sep), Medtronic reported fiscal first-quarter results that beat estimates and raised its full-year 2027 outlook on strong heart-device demand; the stock gained as much as 4.7% that day. The same day, the company announced an investment of roughly $80m in Pi-Cardia to support complex TAVR innovation and a strategic partnership with Cornerstone Robotics to widen global access to robotic-assisted surgery. Combined with related spending, the total commitment came to about $780m. On Thursday (3 Sep), the Endurant stent graft system received a CE mark update removing a warning tied to ruptured abdominal aortic aneurysm treatment. On Friday (4 Sep), the company filed its 10-Q.
Analyst Ratings
Across 30 covering institutions, 20 rate Medtronic buy or overweight, 9 rate it hold, and none rate it underweight or sell, with 1 having no opinion. The consensus recommendation is buy, with a consensus target of $104.76, about 11.25% above spot. The target range of $85 to $121 points to meaningful disagreement among brokers. Medtronic ranks 3rd out of 142 peers in its medical-device industry for ratings.
The Week Ahead
Medtronic has no earnings event next week, so attention shifts to macro releases. Tuesday (8 Sep) brings the NFIB Small Business Optimism Index, while Thursday (10 Sep) is the heavier session with jobless claims, existing home sales, PPI, and the 10-year note auction. Company executives are also scheduled to speak at upcoming investor conferences, which may add detail to the latest quarter.
In Short
The tension this week: a guidance raise and strategic partnerships send a stronger operating signal, and most brokers rate the stock buy, yet the target spread remains wide. On the latest trading day, the flow split was small-lot buying against large-lot selling. The follow-through to watch is whether these moves convert into growth over the next few quarters, rather than staying as a raised outlook on paper.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.